Monday, March 24, 2014

Gilead scrambles toward hep C cure-all with next-gen combo pill

Gilead scrambles toward hep C cure-all with next-gen combo pill

March 24, 2014 | By

"This molecule is very important (for) Gilead longer term because the "holy grail" of hep C treatment would be a pan-genotypic one pill once per day regimen," Schoenebaum wrote in a hastily penned note to investors Monday morning....
The biotech--under intense criticism for pricing Sovaldi at $84,000 in the U.S. for the 12-week treatment--posted an abstract for the upcoming meeting of the European Association for the Study of the Liver that outlined 100% cure rates among small groups of patients across 6 genotypes taking one of two doses of a Sovaldi combination treatment. The big add here is GS-5816, a next-gen NS5A inhibitor that added the essential ingredient for a new regimen that promises to eliminate any need for interferon as well as ribavirin.

Read more
Subscribe at FierceBiotech
Posted by at
File Under ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)